A

s the national opioid crisis rages, painkiller manufacturers have raked in profits and earned plaudits by reformulating their opioids in an attempt to deter abuse.

But on Tuesday, a federal advisory panel delivered an extraordinary rebuke to one such product on the market, suggesting that Endo Pharmaceuticals’ efforts to make Opana ER harder to crush ended up making things worse by enabling addicts to inject it.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X